AI-generated summary
The authors report a pre-registered secondary analysis of a randomized trial in 219 women receiving chemotherapy for breast cancer, comparing CBT-I, bright light therapy, their combination, and a sleep hygiene control on health-related quality of life. CBT-I was associated with improvement from baseline to post-intervention, while bright light therapy showed no significant between-group effects. Exploratory findings were not confirmed at 6-month follow-up.
- Participants
- 219
- Who or what was studied
- Women receiving chemotherapy for early or advanced breast cancer (mean age 50.67 years)
- Limits stated in the abstract
- Secondary and exploratory analyses, with no significant changes in any group at 6-month follow-up.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
Advances in cancer treatment have led to improved survival rates, but challenges related to health-related quality of life (HRQoL) persist, often exacerbated by sleep disturbances. We present a pre-registered, secondary analysis of HRQoL from a trial of sleep interventions among women with early or advanced breast cancer receiving chemotherapy.
Patients And Methods
This 6-week, multisite, remotely-delivered, randomized controlled trial compared Cognitive Behavioral Therapy for Insomnia (CBT-I), Bright Light Therapy (BLT), their combination (CBT-I + BLT), and an active control (Sleep Hygiene Education, SHE) on HRQoL as measured by the PROMIS-Preference score (anchors: 0 "Dead" to 1 "Full health") at baseline, mid-point (3-weeks), post-intervention (6-weeks), and follow-ups (3&6-months). Interventions involved emails and tailored therapist-assisted intervention sessions.
Results
219 women receiving chemotherapy (Mage 50.67 years) were recruited. At baseline, average HRQoL was low (0.27). CBT-I led to a significant improvement from baseline to post-intervention (b = 0.06; p = 0.012). In contrast, BLT showed no significant effects (all p ≥ 0.519). No CBT-I × BLT interaction was observed (all p ≥ 0.759). Clinically meaningful improvement (≥ MID) was observed in 71.2% of CBT-I participants. Within-group analyses from baseline to post-intervention showed the largest HRQoL improvements in CBT-I and CBT-I + BLT groups (both b = 0.14; p < 0.001); smaller gains were observed in BLT and SHE groups (b = 0.07-0.09; p ≤ 0.024). No significant changes were observed in any group at 6-month follow-up (all p ≥ 0.096). Exploratory analyses suggested benefits of BLT in patients with metastatic disease and greater insomnia severity.
Conclusion
CBT-I was associated with clinically meaningful improvements in HRQoL during chemotherapy. These findings support the integration of CBT-I into supportive care and highlight the need for tailored approaches for patients with advanced disease or persistent insomnia symptoms.
Trial Registration
ACTRN12620001133921.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Randomized controlled trial, Insomnia, Light-emitting diode, Bright light therapy, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.